The Number Your Doctor Didn’t Order

Why ApoB is the cholesterol metric that actually predicts your death — and why it’s still not standard

I want to begin this chapter with a number. Not your LDL. Your LDL — low-density lipoprotein cholesterol — is a measure of the cholesterol content inside low-density lipoprotein particles. It does not count the particles. It does not count the other atherogenic particles carrying their own cholesterol payload toward your arterial walls. It is a measure of the cargo, not the fleet. The number I want to talk about counts the fleet — all the atherogenic lipoprotein particles in your blood, every LDL particle and every VLDL and every IDL and every lipoprotein(a) — and it is called apolipoprotein B, or ApoB.

Here is what happened when cardiologists took this distinction seriously. In 2019, the European Society of Cardiology and European Atherosclerosis Society issued updated guidelines for the management of dyslipidaemias and concluded, based on a comprehensive review of prospective epidemiological studies, randomized clinical trials, and Mendelian randomization analyses, that ApoB is a more accurate measure of cardiovascular risk than LDL cholesterol and should be the primary lipid target in patients at elevated cardiovascular risk. This was not a fringe position put forward by a research group with a hypothesis to defend. This was the consensus of the largest cardiology society in the world, issued in the flagship journal of that society, after reviewing decades of accumulated evidence.

And yet. In the average primary care visit in the United States in 2024, ApoB is not ordered. It is not on the standard lipid panel that is included in the basic metabolic workup. It is not on the report you received from your last physical. The gap between what the evidence says and what gets ordered in the average clinic is real, it is wide, and it is killing men who were told their cholesterol was fine.

This chapter is about why that gap exists, what ApoB actually is, how to get it measured, and what to do with the result.

The Cholesterol Confusion

Before we can talk about ApoB, we need to spend a moment on what LDL actually is — because the way most patients understand cholesterol is not quite how the biology works, and that misunderstanding is part of why the ApoB gap exists.

Cholesterol is a molecule, not a particle. It does not travel through the bloodstream on its own — it is hydrophobic and cannot dissolve in water-based blood. To move cholesterol from the liver to the tissues and back, the body packages it inside lipoproteins: small spherical particles made of a phospholipid shell with proteins embedded on the outside. The different lipoproteins are named for their density — very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) — and they differ in size, composition, and function.

Standard LDL cholesterol, or LDL-C, measures the total amount of cholesterol carried inside LDL particles. This has been clinically useful for decades, and the evidence that elevated LDL-C predicts cardiovascular events is real and established. But LDL-C has a problem: it does not measure how many LDL particles are present. Two men can have the same LDL-C of 110 mg/dL, but one might have that cholesterol distributed across four hundred large, buoyant LDL particles, and the other might have it distributed across seven hundred small, dense LDL particles. In cardiovascular terms, these are not equivalent situations.

The reason they are not equivalent brings us to the central biology.

The ApoB Mechanism: One Particle, One Protein, One Count

Every atherogenic lipoprotein — LDL, VLDL, IDL, lipoprotein(a) — carries exactly one molecule of apolipoprotein B on its outer surface. One ApoB per particle, without exception. This is not a statistical approximation. It is structural biology: ApoB-100 is the scaffolding protein that holds the LDL particle together, and each particle has exactly one.

The implication is elegant and clinically useful: measuring ApoB gives you the exact count of every atherogenic lipoprotein particle in the blood, because each particle carries exactly one ApoB molecule. An ApoB of 80 mg/dL means there are a specific, calculable number of atherogenic particles per unit of blood. An ApoB of 120 mg/dL means substantially more particles, each of which is capable of crossing the arterial endothelium and becoming part of an atherosclerotic plaque.

Why does particle number matter more than cholesterol content? Because the atherogenic process is driven by the entry of lipoprotein particles into the arterial wall — a process that depends on particle concentration in the blood and the gradient across the endothelium. A large LDL particle and a small LDL particle carry different amounts of cholesterol, but both carry one ApoB, and both are capable of crossing the endothelium and initiating plaque formation. The large particle carries more cholesterol per crossing, but the small, dense particle is more likely to cross in the first place because it is more easily retained in the subendothelial space.

The result is a situation in which men with normal LDL-C but high ApoB — more particles, smaller average size, often associated with insulin resistance, elevated triglycerides, and metabolic syndrome — are carrying significantly elevated cardiovascular risk that their standard lipid panel is not capturing.

A physiological review published in the Journal of the American Heart Association in 2022 by Sniderman and colleagues formalized the argument for ApoB’s superiority: ApoB measures directly the number of potentially atherogenic particles, is not subject to the mathematical discordance that affects LDL-C calculation, and better captures the lipid-driven cardiovascular risk in patients with metabolic syndrome, hypertriglyceridemia, and diabetes — the precise phenotype produced by the upstream chain of stress, cortisol dysregulation, visceral adiposity, and insulin resistance that this book has been describing.

The Discordance Problem: When Your LDL Lies

The clinical importance of the LDL-C versus ApoB distinction becomes most acute in the case of discordance — situations in which LDL-C and ApoB give different pictures of risk.

In patients with metabolic syndrome — defined by a combination of abdominal obesity, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, and elevated fasting glucose — the liver produces a pattern of small, dense, triglyceride-rich VLDL particles. These particles are metabolically processed into small, dense LDL particles. The result is a man who carries a high number of atherogenic particles — high ApoB — while his total cholesterol content in those particles is relatively low, because small, dense LDL carries less cholesterol per particle. His LDL-C appears acceptable. His ApoB reveals elevated particle burden.

This is the clinical scenario I see regularly in my practice, and it is the scenario that most concerns me. The man with a waist circumference above forty inches, fasting triglycerides between 150 and 250 mg/dL, and an HDL below 45 mg/dL is producing exactly this pattern. His LDL might be 108 mg/dL — reassuringly below the 130 threshold that many physicians use as a rough treatment guideline. His ApoB is 115 mg/dL or higher. His cardiovascular risk, properly estimated, is substantially higher than his LDL-C suggests.

The Multi-Ethnic Study of Atherosclerosis analysis by Marston and colleagues published in JAMA Cardiology in 2022 provided some of the strongest population-level evidence for this discordance’s clinical significance. Among 6,674 participants from MESA, ApoB had stronger and more consistent associations with incident cardiovascular events than LDL-C across all subgroups — and the advantage was most pronounced precisely in the metabolic syndrome phenotype. The men for whom ApoB matters most are the men whose LDL is most likely to be misleading.

What Mendelian Randomization Tells Us

There is an important methodology called Mendelian randomization that deserves mention in this chapter, because it is how we establish causal relationships in cardiovascular lipid research without being able to run experiments on human arteries.

Mendelian randomization uses naturally occurring genetic variants — variants that people are born with and that influence specific biological traits, like the levels of specific lipoproteins — as natural experimental conditions. If a genetic variant that reliably raises ApoB levels is also associated with higher rates of cardiovascular events in large population studies, this provides evidence that ApoB elevation causes cardiovascular events, not merely that it is correlated with them. The logic is that genetic assignment is effectively random (like being assigned to a treatment or control group in a randomized trial), which removes many of the confounding factors that plague observational studies.

Mendelian randomization studies on ApoB — using variants in genes like APOE, PCSK9, and others — have consistently found that genetic predisposition to higher ApoB levels is causally associated with higher cardiovascular risk, and that this causal relationship holds independently of the cholesterol content of those particles. The causal case for ApoB as a primary driver of atherosclerosis, rather than merely a marker, is now among the strongest in all of cardiovascular medicine.

The 2020 review by Borén and colleagues published in the European Heart Journal made this case systematically: LDL particles cause atherosclerosis, ApoB particles cause atherosclerosis, and the best single measure of atherogenic particle burden — and therefore of the magnitude of this causal driver — is ApoB. This is the scientific foundation for the ESC’s clinical recommendation.

The Other Number: Lipoprotein(a)

While we are talking about the lipid measurements that your standard panel is not including, I need to spend meaningful time on lipoprotein(a), or Lp(a). If ApoB is the number that most men don’t know they should have measured, Lp(a) is the number that most people — physicians included — don’t think to measure at all.

Lipoprotein(a) is a genetically determined LDL-like particle with an additional protein attached — apolipoprotein(a), connected to the ApoB backbone by a disulfide bond. This additional protein carries oxidized phospholipids that make Lp(a) not only atherogenic but also pro-thrombotic: it promotes both the buildup of plaque and the blood-clotting events that cause that plaque to become an acute cardiac event. It is, in the parlance of vascular biology, a double threat.

Approximately twenty percent of the population carries Lp(a) concentrations above the threshold generally considered to confer elevated cardiovascular risk — above 50 mg/dL or 125 nanomoles per liter, depending on the assay used. In individuals of African descent, Lp(a) prevalence at elevated levels is higher. The critically important feature of Lp(a) is that its levels are approximately eighty percent determined by genetics. Diet does not meaningfully reduce Lp(a). Exercise does not meaningfully reduce Lp(a). Standard statin therapy reduces LDL-C substantially but reduces Lp(a) by only zero to fifteen percent. A man with an Lp(a) of 200 nmol/L is carrying a cardiovascular risk burden that is invisible to his lipid panel, that is substantially immune to lifestyle modification, and that he has been carrying since birth.

Mendelian randomization studies have established that each 50 mg/dL increment in Lp(a) concentration increases cardiovascular risk by approximately twenty-five percent. This is not a small effect. The American Heart Association’s 2024 review in Arteriosclerosis, Thrombosis, and Vascular Biology confirmed Lp(a)‘s causal role in both atherosclerotic cardiovascular disease and aortic stenosis, and the 2026 American College of Cardiology guideline update recommends testing all adults with established ASCVD or high ten-year risk.

The reason Lp(a) is not measured routinely is partly historical — it was technically difficult to assay consistently until recently — and partly institutional inertia. The test is now widely available, typically costs twenty to forty dollars, and needs to be done exactly once in a man’s lifetime, since the value changes very little over time. For men with premature cardiovascular disease in their family, for men who have had cardiovascular events despite well-controlled conventional risk factors, and for any man of African descent reading this book, I consider Lp(a) measurement mandatory.

For most men, knowing a high Lp(a) value does not yet mean there is a specific pharmacological treatment available to normalize it — though RNA-based therapies in late-stage clinical trials are showing remarkable efficacy, with results expected imminently. What knowing a high Lp(a) does mean is that the rest of the cardiovascular risk portfolio — ApoB, blood pressure, blood sugar, inflammation, CAC score — needs to be managed more aggressively, because the Lp(a) contribution to risk cannot itself be reduced. You are carrying a loaded baseline. Everything else needs to be lower.

Why ApoB Isn’t on Your Last Lab Report

I am often asked why, if ApoB is the superior measurement that the ESC recommends, it is not included in standard lipid panels in the United States. The answer is a mixture of historical legacy, reimbursement inertia, and physician training.

The standard lipid panel — total cholesterol, LDL-C calculated or measured, HDL-C, and triglycerides — was established as the clinical default in the 1980s and 1990s, when the Framingham Heart Study’s LDL-C associations were the dominant evidence base and the calculation tools for LDL-C were available at minimal cost. Cardiovascular guidelines in the United States moved more slowly than European guidelines toward ApoB as a primary recommendation, and the calculation of LDL-C is so embedded in clinical workflow and electronic health record systems that changing it requires institutional, regulatory, and educational shifts that have not yet fully materialized.

Additionally, LDL-C calculated from the Friedewald equation — the formula used in most standard lab reports — actually underestimates true LDL-C specifically when triglycerides are elevated and LDL-C is in the lower range, which is precisely the metabolic syndrome scenario where the discordance with ApoB is most clinically consequential. The error is worst in exactly the patients where the correct measurement matters most.

The practical implication for you, reading this book: ApoB is a standard laboratory measurement available through Quest Diagnostics, LabCorp, and essentially every major clinical laboratory in the United States. It typically costs thirty to fifty dollars out of pocket and is covered by most insurance plans when ordered appropriately. The way to get it is to ask your physician at your next visit. Not to request “a better lipid panel.” To ask specifically: “I’d like my ApoB and Lp(a) measured — can you add those to my next lipid panel?” The specificity of the request matters.

The Target Number

Knowing your ApoB only matters if you know what to do with it. Here is the current evidence-based framework.

The European Society of Cardiology’s 2019 guidelines set ApoB targets based on overall cardiovascular risk:

• For men at very high cardiovascular risk (established atherosclerotic disease, diabetes with end-organ damage, chronic kidney disease, or estimated ten-year ASCVD risk greater than ten percent): ApoB below 65 mg/dL
• For men at high cardiovascular risk (markedly elevated single risk factors, ten-year risk five to ten percent, diabetes without end-organ damage): ApoB below 80 mg/dL
• For men at moderate or lower cardiovascular risk: ApoB below 100 mg/dL

For context, the median ApoB in American men is approximately 90–95 mg/dL. A man with metabolic syndrome who has never been treated for lipid abnormalities because his LDL-C was 108 mg/dL might easily have an ApoB of 115 mg/dL or above — placing him in a category that warrants active clinical management that he has never been offered.

The ApoB-Statin Question

If your ApoB comes back elevated, one of the most likely clinical conversations you will have is about statins. This deserves a careful word.

Statins — HMG-CoA reductase inhibitors, the class of drugs that includes atorvastatin, rosuvastatin, pravastatin, and others — reduce LDL-C primarily, but they also reduce ApoB, typically by thirty to fifty percent depending on the agent and dose. They reduce cardiovascular events robustly, with a strong and consistent evidence base: the 2010 Cholesterol Treatment Trialists’ meta-analysis across twenty-seven trials found that each 1 mmol/L reduction in LDL-C was associated with a twenty-two percent reduction in major cardiovascular events. The evidence for statin-mediated event reduction is among the most replicated findings in clinical medicine.

The controversy around statins — which is real and has been amplified considerably by non-medical voices online — centers primarily on muscle side effects and, in some circles, on a general skepticism about pharmaceutical solutions to metabolic problems. On the question of side effects: muscle aches attributable to statins occur in roughly five to ten percent of patients, are dose-dependent, and are generally mild and reversible with dose reduction or agent change. The claim that statins cause significant harm in the majority of patients who take them is not consistent with the randomized controlled trial data. On the question of whether lifestyle modification is preferable: the cardiologist’s honest answer is yes, where effective, and also that lifestyle modification and statin therapy are not mutually exclusive, that many men cannot achieve sufficient ApoB reduction through lifestyle alone, and that a decision about statin therapy is a conversation to have with your physician based on your individual risk, not a position to adopt based on podcasts.

I will say this plainly: the man with an ApoB of 120, a family history of premature heart disease, and a CAC score above 100 — which you’ll learn about in the next chapter — who decides not to take a statin because he once read a blog post about their effects on muscle is making a decision with consequences that I have watched play out in real time in my clinic, and the consequences are not good. The conversation belongs between you and your physician, with your numbers on the table.

High-Sensitivity CRP: The Inflammation Companion to ApoB

Before we close the conversation about lipid risk, I want to introduce a measurement that does not measure lipids at all — but whose value is greatest when interpreted alongside ApoB. High-sensitivity C-reactive protein, or hs-CRP, is a marker of systemic inflammation produced by the liver in response to inflammatory cytokines, particularly IL-6. At the sub-clinical levels the hs-CRP assay is designed to detect — between zero and ten milligrams per liter — it provides independent cardiovascular risk information that cannot be derived from standard lipid measurements.

The foundational clinical trial establishing hs-CRP’s practical significance was the JUPITER trial — Justification for the Use of Statins in Prevention — published in the New England Journal of Medicine in 2008. JUPITER randomized 17,802 men and women with LDL-C below 130 mg/dL — below the conventional treatment threshold — but hs-CRP of 2 mg/L or above. Rosuvastatin reduced the composite cardiovascular endpoint by forty-four percent compared to placebo. This trial proved, in a randomized controlled design, that a man with a low LDL-C but elevated inflammation — a man who would be told his cholesterol looks fine by any standard lipid panel — benefits substantially from statin therapy. The driving signal for treatment selection was not the LDL; it was the hs-CRP.

Clinical interpretation of hs-CRP uses three tiers: below 1 mg/L is low cardiovascular risk; 1 to 3 mg/L is moderate; above 3 mg/L is high, in the absence of acute infection or inflammatory disease that would spuriously elevate the result. The average hs-CRP in a healthy, lean, non-smoking forty-five-year-old man is approximately 0.5 to 1 mg/L. In a man with metabolic syndrome, chronic psychological stress, disrupted sleep, and visceral adiposity — the composite phenotype described throughout this book — hs-CRP values of 2 to 5 mg/L are common and clinically meaningful.

Why does inflammation predict cardiovascular events independently of lipids? Because atherosclerotic plaque rupture — the acute event that causes most heart attacks — is primarily an inflammatory event, not a structural one. The fibrous cap of a vulnerable plaque ruptures when macrophage-mediated inflammation weakens the cap matrix from the inside. Systemic inflammation, measured by hs-CRP, reflects the activity level of this inflammatory process in a way that lipid measurements do not.

The hs-CRP is available on most standard comprehensive metabolic panels or as a standalone order, typically costs fifteen to thirty dollars, and adds information to the ApoB measurement that the ApoB alone does not provide. A man with ApoB of 108 and hs-CRP of 0.4 is in a substantially different position from one with ApoB of 108 and hs-CRP of 3.8 — even though their particle burden is identical. The first man has a metabolic liability. The second has a metabolic liability and active vascular inflammation. Treatment urgency is not the same.

Putting ApoB in Clinical Context

ApoB does not exist in isolation. It is the lipid dimension of a cardiovascular risk portrait that includes blood pressure, blood sugar, inflammatory status, sleep quality, hormonal balance, and structural plaque burden. The clinical intelligence of ApoB is greatest when it is interpreted alongside these other dimensions.

The emerging preventive cardiology standard — articulated most clearly by researchers and clinicians working at the forefront of this field, and now increasingly reflected in guideline recommendations — is a composite assessment that includes: ApoB (the lipid traffic measure), Lp(a) (the genetic baseline), high-sensitivity CRP (the inflammation signal), fasting insulin or HOMA-IR (the insulin resistance indicator), blood pressure with ambulatory monitoring where possible, and coronary artery calcium scoring (the structural audit of what has already been deposited). Together, these measurements give a complete picture of where a man’s arterial system stands today — not a statistical extrapolation from population averages, but a direct measurement of his specific biology.

The man with ApoB of 110, Lp(a) of 180 nmol/L, fasting insulin of 14, and a CAC score of 80 at age 48 is in a different situation from the man with the same ApoB but Lp(a) of 40, fasting insulin of 7, and CAC of zero. The first man needs aggressive management now. The second man needs surveillance and moderate intervention. Neither picture is visible from a standard lipid panel alone.

That complete picture is what you are building as you read this book.

Clinical Pearl — If you read nothing else in this chapter: The European Society of Cardiology’s 2019 guidelines concluded that ApoB is a more accurate measure of cardiovascular risk than LDL cholesterol and should be the primary lipid target in clinical care. This is not a fringe position — it is the consensus of the world’s largest cardiology society, supported by Mendelian randomization data, prospective cohort studies, and randomized trial analyses, summarized by Sniderman and colleagues in the Journal of the American Heart Association (2022). If your last lipid panel did not include ApoB, you have received an incomplete cardiovascular risk assessment. The test costs thirty to fifty dollars. Ask your physician to add it.

The composite patient in this chapter is Marcus’s colleague at the hospital: Andrew, 46, a gastroenterologist in private practice who has been “watching his cholesterol for years.” His most recent lipid panel showed total cholesterol of 192 mg/dL, LDL-C of 108 mg/dL, HDL of 38 mg/dL, and triglycerides of 248 mg/dL. His primary care physician told him his LDL was fine and suggested he reduce saturated fat. Nobody ordered an ApoB or Lp(a). Andrew came to see me after a colleague of his age had a myocardial infarction during a morning run. His ApoB came back at 124 mg/dL. His Lp(a) was 142 nmol/L. His hsCRP was 3.4 mg/L. His fasting insulin was elevated. He had been told he was fine. He was not fine. He is now on a statin, with an ApoB at goal three months later, and has lost eighteen pounds through dietary modification. His metabolic picture is dramatically different from what it was the year he was told his cholesterol looked good.

What to Do This Week

1. Look at your most recent lab report — your last lipid panel or physical bloodwork. Find the LDL-C result. Now note whether ApoB is anywhere on that report. If it is not, write this down as a question for your next physician interaction: “I’d like my ApoB and Lp(a) added to my next lipid panel.”

2. If you have a history of premature cardiovascular disease in your family — a father or brother with a heart attack or stenting procedure before sixty, a mother before seventy — call your physician’s office this week and ask specifically about Lp(a) testing. This is a one-time test that is particularly important if you have any family pattern of premature cardiovascular events.

3. If your last triglycerides were above 150 mg/dL and your HDL was below 45 mg/dL, write those numbers down. This combination is the metabolic phenotype most likely to produce an ApoB that is worse than your LDL-C suggests. It needs to be interpreted alongside an ApoB measurement at your next visit.

Transition to Chapter 7

ApoB tells you what your arteries are being exposed to — the daily lipid traffic crossing your endothelium. But lipid traffic is only half the story. Chapter 7 is about what your arteries have already done with decades of that exposure: the calcium that has been deposited in the walls of your coronary arteries, the score that represents your vascular age, and the test that takes twelve minutes and costs a hundred dollars and could change the clinical conversation you have for the rest of your life.